Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicines company that operates at the intersection of computational and experimental technologies. Their innovative approach to drug discovery focuses on understanding protein motion, which they liken to viewing proteins in HD movies rather than static images. This unique perspective allows them to target previously intractable or inadequately addressed drug targets. The company's proprietary Dynamo™ platform integrates various experimental and computational approaches to drug protein targets, enabling a more efficient and effective drug discovery process. Relay Therapeutics primarily focuses on developing small molecule medicines for precision medicine targets, with an initial emphasis on oncology and genetic diseases. Their pipeline includes promising candidates such as RLY-4008, RLY-2608, and RLY-1971, targeting various forms of cancer. The company collaborates with major pharmaceutical firms like Pfizer and has partnerships with diagnostic companies such as Foundation Medicine to develop companion diagnostics for their drug candidates. Relay Therapeutics' approach aims to revolutionize drug discovery by leveraging advanced technologies to visualize and understand protein behavior in unprecedented detail, potentially leading to more effective and targeted therapies for patients.